Akanda (AKAN) Competitors $1.58 -0.09 (-5.39%) Closing price 01/17/2025 03:59 PM EasternExtended Trading$1.60 +0.02 (+1.52%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends AKAN vs. ENSC, MYNZ, SPRC, CYCN, BFRI, EGRX, ADXN, AIMD, NLSP, and OBSVShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Ensysce Biosciences (ENSC), Mainz Biomed (MYNZ), SciSparc (SPRC), Cyclerion Therapeutics (CYCN), Biofrontera (BFRI), Eagle Pharmaceuticals (EGRX), Addex Therapeutics (ADXN), Ainos (AIMD), NLS Pharmaceutics (NLSP), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Ensysce Biosciences Mainz Biomed SciSparc Cyclerion Therapeutics Biofrontera Eagle Pharmaceuticals Addex Therapeutics Ainos NLS Pharmaceutics ObsEva Akanda (NASDAQ:AKAN) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Do institutionals & insiders hold more shares of AKAN or ENSC? 1.0% of Akanda shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 20.4% of Akanda shares are owned by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is AKAN or ENSC more profitable? Akanda has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Akanda's return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A Ensysce Biosciences -179.26%-292.81%-158.83% Does the MarketBeat Community prefer AKAN or ENSC? Ensysce Biosciences received 3 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformAkandaN/AN/AEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Does the media refer more to AKAN or ENSC? In the previous week, Akanda's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score. Company Overall Sentiment Akanda Neutral Ensysce Biosciences Neutral Which has stronger valuation and earnings, AKAN or ENSC? Ensysce Biosciences has higher revenue and earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$2.16M1.05-$32.28MN/AN/AEnsysce Biosciences$2.23M4.56-$10.61M-$27.44-0.28 Which has more volatility and risk, AKAN or ENSC? Akanda has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. SummaryAkanda and Ensysce Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.25M$1.22B$5.34B$9.11BDividend YieldN/AN/A5.37%4.00%P/E RatioN/A21.3957.4913.22Price / Sales1.055.741,275.6876.05Price / CashN/A9.9836.6032.90Price / Book-0.022.044.874.58Net Income-$32.28M-$53.10M$118.05M$224.84M7 Day Performance3.27%0.29%1.50%2.37%1 Month Performance12.06%-0.38%2.55%4.40%1 Year Performance-95.22%-5.93%25.83%20.11% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.58-5.4%N/A-95.2%$2.25M$2.16M0.00110ENSCEnsysce Biosciences0.0181 of 5 stars$6.96-7.1%N/A-54.6%$9.09M$2.23M-0.2510MYNZMainz Biomed2.6371 of 5 stars$4.53+5.8%$120.00+2,549.0%-88.8%$9.07M$917,203.00-0.0730Positive NewsGap UpSPRCSciSparc0.6391 of 5 stars$0.87+6.7%N/A-82.0%$9.00M$1.75M0.004Gap DownCYCNCyclerion Therapeutics2.2592 of 5 stars$3.30+0.3%N/A-16.4%$8.94M$1.62M0.0030Positive NewsGap UpBFRIBiofrontera3.1782 of 5 stars$1.14+1.8%$7.00+514.0%-32.9%$8.83M$35.36M-0.5070EGRXEagle PharmaceuticalsN/A$0.65+16.1%N/A-85.5%$8.44M$257.55M0.00100ADXNAddex Therapeutics2.6571 of 5 stars$7.81+3.8%$30.00+284.3%+13.5%$8.27M$556,045.00-22.9630Gap UpAIMDAinos1.3279 of 5 stars$0.58-17.6%N/A-46.5%$8.24M$40,633.000.0040Gap DownNLSPNLS PharmaceuticsN/A$2.10-9.5%N/A+297.9%$8.01MN/A0.006Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst Forecast Related Companies and Tools Related Companies ENSC Competitors MYNZ Competitors SPRC Competitors CYCN Competitors BFRI Competitors EGRX Competitors ADXN Competitors AIMD Competitors NLSP Competitors OBSV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKAN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
